![](/img/cover-not-exists.png)
Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in IRAN
Rezaee, Mehdi, Izadi, Sadegh, Keshavarz, Khosro, Borhanihaghighi, Afshin, Ravangard, RaminLanguage:
english
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2018.1560750
Date:
December, 2018
File:
PDF, 1.13 MB
english, 2018